research Contraceptive implants considered 'safe'
Some birth control pills increase blood clot risk; use them for specific conditions only.
Search
for
Sort by
Research
30-60 / 1000+ results research Efficacy of Letrozole (LE) Combined with Cabergoline (CE) in Comparison to LE alone in ovulation induction among patients with Polycystic Ovarian Syndrome (PCOS) and Hyperprolactinemia (HP)
Letrozole combined with Cabergoline improves ovulation and pregnancy rates in women with PCOS and high prolactin levels compared to Letrozole alone.
research A possible solution for hair loss by inhibiting corticotropin-releasing factor (CRF) receptor from traditional Chinese medicine
Caribine from traditional Chinese medicine may help treat hair loss.
research The manipulation of the cedrol metabolism pathway by baricitinib and its immune interaction mechanism against chemotherapy-induced alopecia
research Bioavailability File: Bicalutamide
Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
research Combined hormonal contraception and venous thromboembolism
Birth control pills increase the risk of blood clots, especially within the first year and with certain types.
research Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Bicalutamide
research β-sitosterol in Yijing Hugui decoction prevents cyclophosphamide-induced premature ovarian insufficiency via the AKT1/Nrf2 pathway
research Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial
Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.
research EFFECTS OF A LOW‐DOSE DESOGESTREL‐ETHINYLESTRADIOL COMBINATION ON HIRSUTISM, ANDROGENS AND SEX HORMONE BINDING GLOBULIN IN WOMEN WITH A POLYCYSTIC OVARY SYNDROME
Low-dose oral contraceptives reduced hair growth and testosterone levels in women with polycystic ovary syndrome.
research Dual-drug nanostructured lipid carriers of spironolactone and 2-deoxy-D-ribose for targeted follicular delivery in androgenetic alopecia
Nanocarriers with spironolactone and 2-deoxy-D-ribose may improve hair loss treatment by targeting hair follicles directly.
research Changes in the serum metabolomics of polycystic ovary syndrome before and after compound oral contraceptive treatment
COC treatment improves hormone and metabolic levels in PCOS patients.
research Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Evolving CRBN ligands enhance the drug-like properties of protein degraders
Improved CRBN ligands make protein degraders more effective and drug-like.
research Clinical effectiveness of ethinylestradiol-cyproterone acetate and raloxifene combination therapy in polycystic ovary syndrome-associated infertility
The combination therapy effectively treats infertility in PCOS without major side effects.
research Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case–control analysis using German claims data
Some birth control pills increase young women's risk of blood clots more than others.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
research Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
Vismodegib is effective for basal cell carcinoma but has severe side effects.
research Результаты применения комбинированных оральных контрацептивов с дроспиреноном и финастерида у женщин с синдромом поликистозных яичников без метаболических нарушений
Both finasteride and drospirenone treatments improved symptoms and increased pregnancy rates in women with polycystic ovary syndrome.
research Sequential small-molecule therapy for lymphocytic cicatricial alopecia: A multicenter prospective cohort pilot study
The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
research [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].
Some gonadal hormone drugs can block filovirus entry into cells.
research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.